GlassScriptPhysician profile
Susan Sinha
NPI 1710049382
$2,400.75
in general payments reported to CMS, 2019-2025
29 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $323 · 2021: $406 · 2022: $283 · 2023: $320 · 2024: $274 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.42 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $346.60 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $311.87 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $247.60 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $158.44 | 2020-2024 | Farxiga |
| Lilly USA, LLC | $150.99 | 2020-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.75 | 2019-2022 | |
| Exact Sciences Corporation | $73.36 | 2023-2024 | Cologuard Collection Kit |
| Optinose US, INC. | $57.33 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $52.73 | 2024 | Gemtesa |
| Glaxosmithkline, LLC. | $45.96 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $37.85 | 2020 | |
| Orexo US, INC. | $33.98 | 2019-2020 | |
| Amarin Pharma, INC. | $31.50 | 2021 | |
| Indivior INC. | $26.27 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26.14 | 2020-2021 | |
| Dexcom, INC. | $23.15 | 2024 | Dexcom G6 Transmitter |
| Seqirus USA INC | $21.51 | 2024 | Flucelvax |
| Endo Pharmaceuticals INC. | $19.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.58 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.31 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.08 | 2023 | Livalo, Seglentis |
| Alk-Abello, INC | $16.19 | 2023 | Odactra, Ragwitek, Grastek |
| Tolmar, INC. | $15.45 | 2025 | Jatenzo |
| Dermira, INC. | $15.04 | 2020 | |
| Boston Scientific Corporation | $14.98 | 2021 | |
| Linus Health, INC. | $13.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.87 | 2020 | |
| Merck Sharp & Dohme LLC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.